Vaccines Market Overview
As per Econ Market Research analysis, the Global Vaccines Market valuation stood at US$ 88.4 Billion in 2026 and is expected to reach US$ 126.26 Billion by 2035, growing at a steady CAGR of 4.04% from 2026 to 2035. 2025 serves as the base year.
A pivotal point in the history of healthcare was reached with the introduction of vaccinations to the world market. Biologically produced compounds known as vaccines are intended to boost the immune system and guard against a range of viral illnesses. Their appearance in the early 20th century coincided with a significant advancement in public health due to the creation of vaccines against illnesses like polio and smallpox.
The market for vaccines has grown dramatically over time, and a large selection of vaccines are now available to prevent a variety of infectious diseases, including as COVID-19, influenza, measles, mumps, rubella, and hepatitis. Globally, vaccinations have prevented countless deaths and significantly lessened the burden of preventable diseases. They have helped to almost completely eradicate polio and eradicate smallpox. In the field of vaccination, ongoing research and development have led to the creation of novel, safer, and more effective vaccine formulations, such as mRNA vaccines, which became well-known during the COVID-19 pandemic.
The market for vaccines is a vital part of the global healthcare system, highlighting the role that immunization plays in public health initiatives and disease prevention. In order to protect world health, efforts are still being made to create new vaccines, increase accessibility, and guarantee equitable distribution. The area is very active and changing.
Market Dynamics
The market for vaccinations demonstrates intricate and dynamic dynamics that are fueled by a confluence of market factors, public health regulations, and scientific discoveries. Continuous research and development that results in the production of new and improved vaccines is a major element driving the market. Innovations in technology, such mRNA vaccine platforms, have completely changed the vaccination industry by enabling more rapid vaccine development and a wider range of uses.
The market is also greatly impacted by public health efforts and government legislation. Government funding and procurement tactics affect availability and distribution of vaccinations, whereas vaccination programs, mandates, and incentives increase demand for vaccines. The development of vaccines is greatly aided by financial and approval processes that are expedited for vaccine makers. Additionally, events related to global health, such pandemics and disease outbreaks, have an impact on market dynamics. The COVID-19 pandemic hastened efforts to produce, distribute, and conduct research on vaccines, underscoring the importance of having quick reaction capabilities.
The market for vaccines is not without difficulties. There are still problems with accessibility and affordability, and high-income and low-income nations distribute vaccines differently. Achieving high vaccination rates is further hampered by vaccine reluctance and disinformation. Public health emergencies, government regulations, scientific advancements, and socioeconomic considerations all influence the vaccination industry. To ensure that vaccinations continue to be effective in preventing and controlling infectious illnesses on a worldwide scale, striking a balance between innovation, accessibility, and fairness is a crucial task.
Market Drivers
Advancements in Vaccine Technology
These developments have enhanced disease prevention and control by revolutionizing the creation, manufacturing, and effectiveness of vaccinations. The creation and broad use of mRNA vaccination platforms is one noteworthy innovation. The Pfizer-BioNTech and Moderna COVID-19 vaccines are two examples of how this technology enables the quick design and manufacture of vaccinations. It has the benefit of flexibility, making it possible to react quickly to newly discovered infectious diseases. This discovery has not only changed how vaccines are developed, but it has also raised the bar for vaccine efficacy.
Other developments in vaccination science include the use of viral vector, DNA-based, and creative adjuvants in addition to mRNA technology. By improving vaccination safety and immunogenicity, these technologies create new avenues for the treatment of difficult-to-cure diseases. Furthermore, the integration of informatics, Data Analytics, and Artificial Intelligence in vaccine research has expedited target identification, clinical trial design, and safety monitoring. These digital innovations streamline the vaccine development process and enhance the understanding of vaccine performance.
Expanding Aging Population
People who live longer are more vulnerable to health issues associated with aging, such as compromised immune systems and higher risks of infectious diseases. This change in the population highlights the value of vaccinations as a vital instrument for preserving the health and wellbeing of the elderly. Elderly people are frequently more vulnerable to serious side effects from diseases including influenza, pneumonia, shingles, and other illnesses that can be prevented by vaccination.
As a result, the need for vaccinations designed to specifically meet the immunological needs of the elderly population is rising. This has prompted studies and the creation of vaccinations that provide older persons with improved protection. Furthermore, the significance of immunization for the elderly is being emphasized in public health policies and guidelines, which is boosting demand and opening up potential for vaccine manufacturers. Governments and healthcare organizations are increasing the number of immunization campaigns aimed at this population since they understand how much it can save expenses and enhance the lives of the elderly.
Restraints:
To guarantee safety and efficacy, vaccine development necessitates thorough pre-clinical and clinical testing as well as rigorous scientific research. There is a significant time and resource commitment for these research. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have strict regulatory criteria that must be met. This requires a lot of documentation and quality control procedures, which raises the cost of development. It is costly to carry out extensive clinical trials with a variety of participant populations. Although these studies might be quite expensive, they are essential to proving the safety and effectiveness of vaccinations. It is quite expensive to set up vaccine manufacturing facilities and increase output to meet demand worldwide, particularly for more recent technologies like mRNA vaccines. These high development costs often result in elevated prices for vaccines, which can be a barrier to access, particularly in lower-income countries.
Manufacturing Challenges and Supply Chain Issues
The process of making vaccines is extremely intricate and specialized, entailing the cultivation, inactivation, and formulation of the vaccine',s active ingredient. Any departure from the exact production procedures can result in problems with efficacy or safety. Strict testing and quality control methods are necessary to guarantee the efficacy and safety of vaccinations, and they can be expensive and time-consuming. Specialized facilities with restricted manufacturing capacity are used to generate a large number of vaccinations. Increasing vaccine production to fulfill spikes in demand like pandemics.
The worldwide supply chain for vaccines is a network of raw materials, production sites, and distribution networks that is highly interrelated. This chain can have far-reaching effects if it is disrupted, as the COVID-19 pandemic showed. Due to the fact that wealthier countries frequently have better access to vaccinations, manufacturing issues can worsen the global vaccine disparity by placing lower-income countries at a disadvantage. Obtaining licenses for industrial facilities and other regulatory requirements can be expensive and time-consuming.
Opportunities:
Increasing Focus on Preventive Healthcare
There is a higher need for vaccines as illness prevention is prioritized more. In order to protect their health and the health of their communities, people are more likely to actively seek out immunization. Governments and medical institutions are spending more money on public health initiatives to spread the word about the value of immunizations. Increased market prospects result from these activities to enhance vaccination uptake.
The pharmaceutical industry is allocating resources to the study and development of novel vaccines, including those that target newly developing infectious illnesses, as it realizes the potential for growth in the vaccines market. The focus on preventative healthcare has fueled ongoing investigation and advancement in the field of vaccination. This results in the creation of innovative vaccinations that are safer, easier to administer, and more.The growing interest in preventive healthcare, especially in emerging markets, expands the consumer base for vaccines, providing opportunities for market expansion.
Increasing Vaccine Adoption in Emerging Markets
The middle class is expanding in many emerging nations, and their disposable income is rising. Increased access to healthcare services, including vaccinations, is made possible by this demographic transition. Emerging market governments are realizing the value of immunization in preventing illness and lowering medical expenses. Adoption of vaccines is being fueled by funding increases and immunization campaigns. Access to and delivery of vaccines are made easier by investments in healthcare infrastructure, such as the growth of medical facilities and immunization programs.
Rising urbanization in emerging economies improves healthcare awareness and accessibility, which encourages urban populations to embrace vaccines. The burden of diseases preventable by vaccination is frequently larger in emerging markets. This fuels the need for vaccinations as an affordable way to lower disease and death rates. International organizations and philanthropic foundations are collaborating with emerging market governments and healthcare organizations to improve vaccine access, affordability, and coverage.
Segment Overview
By Type
Based on type, the global vaccines market is divided into subunit, recombinant, conjugate vaccines, live-attenuated vaccines, inactivated vaccines, toxoid vaccines, DNA vaccines. The conjugate vaccines category dominates the market with the largest revenue share in 2022. Conjugate vaccines combine a weak antigen, such as a polysaccharide from a bacterial cell, with a carrier protein. They are effective against bacterial pathogens with polysaccharide capsules, like Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae. Subunit vaccines consist of purified components of the pathogen, such as proteins or antigens. They are known for their safety as they do not contain the live pathogen.
Subunit vaccines are often used for diseases like hepatitis B and human papillomavirus (HPV). Recombinant vaccines are engineered using genetic techniques to introduce specific genes into a harmless microorganism, which then expresses the desired pathogen component. Examples include the hepatitis B vaccine and some COVID-19 vaccines like those produced by Moderna and Pfizer-BioNTech. Live-attenuated vaccines contain weakened, but still live, forms of the pathogen. They provide robust and long-lasting immunity, as seen in vaccines for measles, mumps, rubella, and the oral polio vaccine.
Inactivated vaccines use pathogen components that have been killed or inactivated, making them safe for immunization. Examples include the polio vaccine (injected form) and the hepatitis A vaccine. Toxoid vaccines are designed to prevent diseases caused by bacterial toxins, such as diphtheria and tetanus. They use inactivated toxins to stimulate an immune response. DNA vaccines introduce genetic material (usually plasmids) encoding specific pathogen antigens into the body, triggering an immune response. While still an emerging technology, they hold promise for conditions like malaria and HIV.
By Age of Administration
Based on the age of administration, the global vaccines market is categorized into pediatric vaccine, adult vaccine. The adult vaccine category leads the global vaccines market with the largest revenue share in 2022. Adult vaccines, on the other hand, are tailored to the specific health needs of adults and the elderly. These vaccines are essential for preventing diseases that can become more prevalent or severe as individuals age. Examples include vaccines for influenza, shingles (herpes zoster), pneumococcal disease, hepatitis B, and human papillomavirus (HPV).
Additionally, adult vaccines can include booster doses or vaccines for travel-related diseases based on a person',s age, health status, and potential exposure risks. Pediatric vaccines are designed for infants, children, and adolescents. They address diseases that are particularly relevant and often more severe in the younger population. Common examples include vaccines for measles, mumps, rubella (MMR), polio, diphtheria, tetanus, pertussis (DTaP), and Haemophilus influenzae type b (Hib). These vaccines are typically administered according to a schedule recommended by health authorities to provide early protection and establish immunity in childhood.
By Diseases
Based on diseases, the global vaccines market is segmented into pneumococcal disease, measles, mumps and varicella, DPT, hepatitis, influenza, typhoid, COVID-19, others. The COVID-19 segment dominates the vaccines market. The COVID-19 vaccine category emerged in response to the global pandemic caused by the novel coronavirus SARS-CoV-2. Multiple vaccines were developed to combat the spread of the virus and mitigate its impact on public health. Pneumococcal vaccines are designed to protect against infections caused by the bacterium Streptococcus pneumoniae, which can lead to conditions like pneumonia, meningitis, and sepsis. These vaccines target three separate viral infections.
Measles, mumps, and varicella (chickenpox) vaccines are crucial in preventing highly contagious and potentially severe childhood diseases. The DPT vaccine is a combination vaccine that provides immunity against three bacterial diseases: diphtheria, tetanus (lockjaw), and pertussis (whooping cough). Hepatitis vaccines protect against various strains of hepatitis viruses, including hepatitis A and hepatitis B, which can lead to liver diseases. The influenza vaccine is administered annually to safeguard against seasonal influenza viruses that can cause respiratory illness and, in some cases, severe complications.
By Route of Administration
Based on route of administration, the global vaccines market is divided into injectable, oral, nasal. The oral category dominates the market with the largest revenue share in 2022. Oral vaccines are taken by mouth, typically in the form of drops, capsules, or liquids. They are designed to stimulate immunity in the gastrointestinal tract and are often used to protect against diseases like polio and rotavirus. Oral vaccines are particularly suitable for mass vaccination campaigns in regions with limited healthcare infrastructure. Injectable vaccines are administered through a needle and syringe, either subcutaneously (under the skin) or intramuscularly (into the muscle). This form of vaccination is widely used and is known for its effectiveness and ability to induce a strong and long-lasting immune response.
Many common vaccines, such as those for measles, mumps, rubella (MMR), hepatitis, and influenza, are administered via injection. Nasal vaccines are administered through the nostrils as a spray or drops. They are designed to target the mucous membranes in the nasal passages and upper respiratory tract. Some nasal vaccines are used to protect against influenza, while others are under development for diseases like COVID-19. Nasal vaccines can offer advantages in terms of ease of administration and enhanced mucosal immunity.
By End User
Based on the end user, the global vaccines market is categorized into community hospitals, hospitals, specialty centres, clinics, others. The community hospitals category leads the global vaccines market with the largest revenue share in 2022. Community hospitals are general medical facilities that serve the healthcare needs of the local community. These hospitals often offer a wide range of medical services, including vaccine administration. They play a vital role in providing routine vaccinations, particularly for residents in their catchment areas. General hospitals, which provide comprehensive medical care and are equipped to handle a wide range of healthcare services, including vaccinations.
Hospitals can administer vaccines to inpatients, outpatients, and individuals with specific medical conditions that require vaccination. Specialty centers are healthcare facilities that focus on specific medical areas, such as pediatric clinics, travel clinics, or specialized vaccine centers. They offer targeted vaccine services and expertise in particular categories of immunization, catering to the unique needs of specific patient groups or circumstances. Clinics, whether public health clinics, private healthcare clinics, or primary care clinics, are essential settings for vaccine administration. They serve as accessible points of care for vaccinations, especially for routine and preventive vaccines.
Market Overview by Region
The global vaccines market is categorized into North America, Europe, Asia-Pacific, and the Rest of the World. Asia-Pacific emerged as the leading region, capturing the largest market share in 2022. A sizable fraction of the world',s population resides in the Asia-Pacific area, which has a diverse demographic environment. Because of this population size, there is a substantial need for vaccines due to the necessity to guard against a variety of infectious diseases.
The burden of infectious diseases, including vaccine-preventable and emerging pathogens, is higher in many Asia-Pacific nations. As a result, vaccination demand has surged as the main method of controlling and preventing chronic illnesses. Over the past few decades, the region has undergone significant economic expansion, which has improved the accessibility of vaccines and the healthcare system. A number of nations have seen increases in the cost and demand for healthcare services, including vaccinations, as a result of rising income levels.
The Asia-Pacific region's numerous governments have acknowledged the significance of vaccinations for public health. To improve vaccine coverage and accessibility, they have put in place immunization campaigns, vaccination programs, and policies. Asia-Pacific is home to a burgeoning Biotechnology and pharmaceutical sector that includes businesses engaged in the creation, production, and research of vaccines. The existence of this industry has improved the region',s standing in the international vaccine market. Due to partnerships between national and international institutions, the area has developed into a center for vaccine research and development, producing cutting-edge vaccinations and medical treatments.
Competitive Landscape
In the global vaccines market, a few major players exert significant market dominance and have established a strong regional presence. These leading companies remain committed to continuous research and development endeavors and actively engage in strategic growth initiatives, including product development, launches, joint ventures, and partnerships. By pursuing these strategies, these companies aim to strengthen their market position, expand their customer base, and capture a substantial share of the market.
Key Players:
Merck and Co., Inc.
Pfizer Inc.
GSK plc
Sanofi
Serum Institute of India Pvt. Ltd.
AstraZeneca plc
Johnson and Johnson
Indian Immunologicals Ltd.
Novasep
Merck KGaA
Charles River Laboratories International, Inc.
uniQure N.V.
Waisman Biomanufacturing
Creative Biogene
Aldevron
Recent Developments
In August 2022, The clinical-stage biopharmaceutical business Affinivax, Inc. (Affinivax), with its headquarters in Cambridge, Massachusetts, has been acquired by GSK plc. Next-generation pneumococcal vaccines are the most developed of a new class of vaccines that Affinivax spearheaded the development of.
In June 2022, ReViral is fully acquired by Pfizer. The acquisition strengthens Pfizer',s commitment to creating both medications and vaccines to help fight the respiratory syncytial virus (RSV) and broadens its anti-infective pipeline.
Vaccines Market Segmentation
| Segment Category | Segment Values |
|---|---|
| Technology |
|
| Indication |
|
| Route of Administration |
|
Key Players
- GSK
- Pfizer
- Merck and Co.
- Sanofi
- Moderna
- Johnson and Johnson
- AstraZeneca
- Serum Institute of India
- CSL Limited
Table of Contents
1. GLOBAL VACCINES MARKET–REPORT OVERVIEW
- 1.1. SCOPE OF THE REPORT
- 1.2. MARKET SEGMENT ANALYSIS
- 1.3. REGULATORY SCENARIO BY REGION/COUNTRY
- 1.4. MARKET INVESTMENT SCENARIO STRATEGIC
- 1.5. MARKET ANALYSIS BY BY TECHNOLOGY (USD MILLION)
- 1.5.1 GLOBAL VACCINES MARKET SHARE BY BY TECHNOLOGY (2026-2035)
- 1.5.2 LIVE ATTENUATED
- 1.5.3 INACTIVATED
- 1.5.4 SUBUNIT AND CONJUGATE
- 1.5.5 TOXOID
- 1.5.6 MRNA AND VIRAL VECTOR
- 1.6. GLOBAL VACCINES MARKET SHARE BY BY TECHNOLOGY IN 2026 & 2035
- 1.7. MARKET ANALYSIS BY BY INDICATION (USD MILLION)
- 1.7.1 GLOBAL VACCINES MARKET SHARE BY BY INDICATION (2026-2035)
- 1.7.2 PNEUMOCOCCAL
- 1.7.3 INFLUENZA
- 1.7.4 HPV
- 1.7.5 HEPATITIS
- 1.7.6 ROTAVIRUS
- 1.7.7 DTP
- 1.7.8 OTHERS
- 1.8. GLOBAL VACCINES MARKET SHARE BY BY INDICATION IN 2026 & 2035
- 1.9. MARKET ANALYSIS BY BY ROUTE OF ADMINISTRATION (USD MILLION)
- 1.9.1 GLOBAL VACCINES MARKET SHARE BY BY ROUTE OF ADMINISTRATION (2026-2035)
- 1.9.2 INTRAMUSCULAR
- 1.9.3 SUBCUTANEOUS
- 1.9.4 ORAL
- 1.10. GLOBAL VACCINES MARKET SHARE BY BY ROUTE OF ADMINISTRATION IN 2026 & 2035
2. DRIVER RESTRAINT CHALLENGE AND OPPORTUNITIES OF VACCINES MARKET
- 2.1. DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
- 2.1.1 MARKET DRIVER ANALYSIS
- 2.1.2 MARKET RESTRAINT ANALYSIS
- 2.1.3 MARKET OPPORTUNITY
- 2.2. MARKET CHALLENGES
3. GLOBAL GROWTH TRENDS
- 3.1. INDUSTRY TRENDS
- 3.1.1 SWOT ANALYSIS
- 3.1.1.1 Strengths
- 3.1.1.2 Weaknesses
- 3.1.1.3 Opportunities
- 3.1.1.4 Threats
- 3.1.2 PESTEL ANALYSIS
- 3.1.2.1 Political Landscape
- 3.1.2.2 Economic Landscape
- 3.1.2.3 Social Landscape
- 3.1.2.4 Technological Landscape
- 3.1.2.5 Environmental Landscape
- 3.1.2.6 Legal Landscape
- 3.1.3 PORTER'S FIVE FORCES ANALYSIS
- 3.1.3.1 Bargaining Power of Suppliers
- 3.1.3.2 Bargaining Power of Buyers
- 3.1.3.3 Threat of Substitute
- 3.1.3.4 Threat of New Entrant
- 3.1.3.5 Competitive Rivalry
- 3.1.1 SWOT ANALYSIS
- 3.2. POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4. POST COVID ANALYSIS
- 4.1. COVID V ANALYSIS
- 4.2. COVID U ANALYSIS
- 4.3. COVID L ANALYSIS
- 4.4. COVID W ANALYSIS
5. COMPANIES ANALYSIS
- 5.1. PLAYERS COVERED: RANKING BY VACCINES MARKET REVENUE
- 5.2. TOP COMPANIES MARKET SHARE (%)
6. EXECUTIVE SUMMARY
7. GLOBAL VACCINES MARKET FORECAST, 2022-2035, (USD MILLION)
- 7.1. GLOBAL VACCINES MARKET REVENUE AND MARKET SHARE BY REGIONS
- 7.2. GLOBAL VACCINES MARKET AND MARKET SHARE BY REGION (2022-2029)
- 7.3. GLOBAL VACCINES MARKET AND MARKET SHARE BY REGION (2030-2035)
- 7.3.1.1 North America
- 7.3.1.2 Europe
- 7.3.1.3 Asia Pacific
- 7.3.1.4 Latin America
- 7.3.1.5 Middle East & Africa
8. NORTH AMERICA VACCINES MARKET ANALYSIS BY COUNTRIES, (USD MILLION)
- 8.1. NORTH AMERICA VACCINES MARKET REVENUE AND MARKET SHARE BY COUNTRIES
- 8.2. NORTH AMERICA VACCINES MARKET AND MARKET SHARE BY COUNTRY (2022-2029)
- 8.3. NORTH AMERICA VACCINES MARKET AND MARKET SHARE BY COUNTRY (2030-2035)
- 8.3.1.1 United States
- 8.3.1.2 Canada
- 8.3.1.3 Mexico
9. EUROPE VACCINES MARKET ANALYSIS BY COUNTRIES, (USD MILLION)
- 9.1. EUROPE VACCINES MARKET REVENUE AND MARKET SHARE BY COUNTRIES
- 9.2. EUROPE VACCINES MARKET AND MARKET SHARE BY COUNTRY (2022-2029)
- 9.3. EUROPE VACCINES MARKET AND MARKET SHARE BY COUNTRY (2030-2035)
- 9.3.1.1 United Kingdom
- 9.3.1.2 Germany
- 9.3.1.3 France
- 9.3.1.4 Spain
- 9.3.1.5 Italy
- 9.3.1.6 Rest of Europe
10. ASIA PACIFIC VACCINES MARKET ANALYSIS BY COUNTRIES, (USD MILLION)
- 10.1. ASIA PACIFIC VACCINES MARKET REVENUE AND MARKET SHARE BY COUNTRIES
- 10.2. ASIA PACIFIC VACCINES MARKET AND MARKET SHARE BY COUNTRY (2022-2029)
- 10.3. ASIA PACIFIC VACCINES MARKET AND MARKET SHARE BY COUNTRY (2030-2035)
- 10.3.1.1 China
- 10.3.1.2 India
- 10.3.1.3 Japan
- 10.3.1.4 Australia
- 10.3.1.5 South Korea
- 10.3.1.6 Rest of Asia Pacific
11. MIDDLE EAST AND AFRICA VACCINES MARKET ANALYSIS BY COUNTRIES, (USD MILLION)
- 11.1. MIDDLE EAST AND AFRICA VACCINES MARKET REVENUE AND MARKET SHARE BY COUNTRIES
- 11.2. MIDDLE EAST & AFRICA VACCINES MARKET AND MARKET SHARE BY COUNTRY (2022-2029)
- 11.3. MIDDLE EAST & AFRICA VACCINES MARKET AND MARKET SHARE BY COUNTRY (2030-2035)
- 11.3.1.1 Saudi Arabia
- 11.3.1.2 South Africa
- 11.3.1.3 Rest of MEA
12. LATIN AMERICA VACCINES MARKET ANALYSIS BY COUNTRIES, (USD MILLION)
- 12.1. LATIN AMERICA VACCINES MARKET REVENUE AND MARKET SHARE BY COUNTRIES
- 12.2. LATIN AMERICA VACCINES MARKET AND MARKET SHARE BY COUNTRY (2022-2029)
- 12.3. LATIN AMERICA VACCINES MARKET AND MARKET SHARE BY COUNTRY (2030-2035)
- 12.3.1.1 Brazil
- 12.3.1.2 Argentina
- 12.3.1.3 Rest of Latin America
13. GLOBAL VACCINES MARKET SEGMENT BY BY TECHNOLOGY, (USD MILLION)
- 13.1. GLOBAL VACCINES MARKET AND MARKET SHARE BY BY TECHNOLOGY (2022-2029)
- 13.2. GLOBAL VACCINES MARKET AND MARKET SHARE BY BY TECHNOLOGY (2030-2035)
- 13.3. NORTH AMERICA VACCINES MARKET AND MARKET SHARE BY BY TECHNOLOGY (2022-2029)
- 13.4. NORTH AMERICA VACCINES MARKET AND MARKET SHARE BY BY TECHNOLOGY (2030-2035)
- 13.5. EUROPE VACCINES MARKET AND MARKET SHARE BY BY TECHNOLOGY (2022-2029)
- 13.6. EUROPE VACCINES MARKET AND MARKET SHARE BY BY TECHNOLOGY (2030-2035)
- 13.7. ASIA PACIFIC VACCINES MARKET AND MARKET SHARE BY BY TECHNOLOGY (2022-2029)
- 13.8. ASIA PACIFIC VACCINES MARKET AND MARKET SHARE BY BY TECHNOLOGY (2030-2035)
- 13.9. MIDDLE EAST & AFRICA VACCINES MARKET AND MARKET SHARE BY BY TECHNOLOGY (2022-2029)
- 13.10. MIDDLE EAST & AFRICA VACCINES MARKET AND MARKET SHARE BY BY TECHNOLOGY (2030-2035)
- 13.11. SOUTH AMERICA VACCINES MARKET AND MARKET SHARE BY BY TECHNOLOGY (2022-2029)
- 13.12. SOUTH AMERICA VACCINES MARKET AND MARKET SHARE BY BY TECHNOLOGY (2030-2035)
13. GLOBAL VACCINES MARKET SEGMENT BY BY INDICATION, (USD MILLION)
- 13.13. GLOBAL VACCINES MARKET AND MARKET SHARE BY BY INDICATION (2022-2029)
- 13.14. GLOBAL VACCINES MARKET AND MARKET SHARE BY BY INDICATION (2030-2035)
- 13.15. NORTH AMERICA VACCINES MARKET AND MARKET SHARE BY BY INDICATION (2022-2029)
- 13.16. NORTH AMERICA VACCINES MARKET AND MARKET SHARE BY BY INDICATION (2030-2035)
- 13.17. EUROPE VACCINES MARKET AND MARKET SHARE BY BY INDICATION (2022-2029)
- 13.18. EUROPE VACCINES MARKET AND MARKET SHARE BY BY INDICATION (2030-2035)
- 13.19. ASIA PACIFIC VACCINES MARKET AND MARKET SHARE BY BY INDICATION (2022-2029)
- 13.20. ASIA PACIFIC VACCINES MARKET AND MARKET SHARE BY BY INDICATION (2030-2035)
- 13.21. MIDDLE EAST & AFRICA VACCINES MARKET AND MARKET SHARE BY BY INDICATION (2022-2029)
- 13.22. MIDDLE EAST & AFRICA VACCINES MARKET AND MARKET SHARE BY BY INDICATION (2030-2035)
- 13.23. SOUTH AMERICA VACCINES MARKET AND MARKET SHARE BY BY INDICATION (2022-2029)
- 13.24. SOUTH AMERICA VACCINES MARKET AND MARKET SHARE BY BY INDICATION (2030-2035)
13. GLOBAL VACCINES MARKET SEGMENT BY BY ROUTE OF ADMINISTRATION, (USD MILLION)
- 13.25. GLOBAL VACCINES MARKET AND MARKET SHARE BY BY ROUTE OF ADMINISTRATION (2022-2029)
- 13.26. GLOBAL VACCINES MARKET AND MARKET SHARE BY BY ROUTE OF ADMINISTRATION (2030-2035)
- 13.27. NORTH AMERICA VACCINES MARKET AND MARKET SHARE BY BY ROUTE OF ADMINISTRATION (2022-2029)
- 13.28. NORTH AMERICA VACCINES MARKET AND MARKET SHARE BY BY ROUTE OF ADMINISTRATION (2030-2035)
- 13.29. EUROPE VACCINES MARKET AND MARKET SHARE BY BY ROUTE OF ADMINISTRATION (2022-2029)
- 13.30. EUROPE VACCINES MARKET AND MARKET SHARE BY BY ROUTE OF ADMINISTRATION (2030-2035)
- 13.31. ASIA PACIFIC VACCINES MARKET AND MARKET SHARE BY BY ROUTE OF ADMINISTRATION (2022-2029)
- 13.32. ASIA PACIFIC VACCINES MARKET AND MARKET SHARE BY BY ROUTE OF ADMINISTRATION (2030-2035)
- 13.33. MIDDLE EAST & AFRICA VACCINES MARKET AND MARKET SHARE BY BY ROUTE OF ADMINISTRATION (2022-2029)
- 13.34. MIDDLE EAST & AFRICA VACCINES MARKET AND MARKET SHARE BY BY ROUTE OF ADMINISTRATION (2030-2035)
- 13.35. SOUTH AMERICA VACCINES MARKET AND MARKET SHARE BY BY ROUTE OF ADMINISTRATION (2022-2029)
- 13.36. SOUTH AMERICA VACCINES MARKET AND MARKET SHARE BY BY ROUTE OF ADMINISTRATION (2030-2035)
14. COMPANY PROFILES
- 14.1. GSK
- 14.1.1 COMPANY DETAIL
- 14.1.2 FINANCIALS (USD MILLIONS)
- 14.1.3 PRODUCT SUMMARY
- 14.1.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.2. PFIZER
- 14.2.1 COMPANY DETAIL
- 14.2.2 FINANCIALS (USD MILLIONS)
- 14.2.3 PRODUCT SUMMARY
- 14.2.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.3. MERCK
- 14.3.1 COMPANY DETAIL
- 14.3.2 FINANCIALS (USD MILLIONS)
- 14.3.3 PRODUCT SUMMARY
- 14.3.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.4. CO.
- 14.4.1 COMPANY DETAIL
- 14.4.2 FINANCIALS (USD MILLIONS)
- 14.4.3 PRODUCT SUMMARY
- 14.4.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.5. SANOFI
- 14.5.1 COMPANY DETAIL
- 14.5.2 FINANCIALS (USD MILLIONS)
- 14.5.3 PRODUCT SUMMARY
- 14.5.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.6. MODERNA
- 14.6.1 COMPANY DETAIL
- 14.6.2 FINANCIALS (USD MILLIONS)
- 14.6.3 PRODUCT SUMMARY
- 14.6.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.7. JOHNSON
- 14.7.1 COMPANY DETAIL
- 14.7.2 FINANCIALS (USD MILLIONS)
- 14.7.3 PRODUCT SUMMARY
- 14.7.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.8. JOHNSON
- 14.8.1 COMPANY DETAIL
- 14.8.2 FINANCIALS (USD MILLIONS)
- 14.8.3 PRODUCT SUMMARY
- 14.8.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.9. ASTRAZENECA
- 14.9.1 COMPANY DETAIL
- 14.9.2 FINANCIALS (USD MILLIONS)
- 14.9.3 PRODUCT SUMMARY
- 14.9.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.10. SERUM INSTITUTE OF INDIA
- 14.10.1 COMPANY DETAIL
- 14.10.2 FINANCIALS (USD MILLIONS)
- 14.10.3 PRODUCT SUMMARY
- 14.10.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.11. CSL LIMITED
- 14.11.1 COMPANY DETAIL
- 14.11.2 FINANCIALS (USD MILLIONS)
- 14.11.3 PRODUCT SUMMARY
- 14.11.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
15. CONCLUSION
16. REFERENCE LINK
17. APPENDIX
- 17.1. METHODOLOGY
- 17.2. RESEARCH DATA SOURCE
- 17.2.1 SECONDARY DATA
- 17.2.2 KEY DATA FROM SECONDARY
- 17.2.3 PRIMARY DATA
- 17.2.4 KEY DATA FROM PRIMARY
- 17.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
- 17.2.6 MARKET ESTIMATION
- 17.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
- 17.2.8 LEGAL DISCLAIMER
18. RESEARCH SCOPE
LIST OF TABLES
- TABLE 1. MARKET SEGMENT
- TABLE 2. GLOBAL VACCINES MARKET GROWTH RATE BY BY TECHNOLOGY (2026-2035)
- TABLE 3. GLOBAL VACCINES MARKET GROWTH RATE BY BY INDICATION (2026-2035)
- TABLE 4. GLOBAL VACCINES MARKET GROWTH RATE BY BY ROUTE OF ADMINISTRATION (2026-2035)
- TABLE 5. COMPANY'S RANK BY VACCINES MARKET REVENUE
- TABLE 6. GLOBAL VACCINES MARKET — MARKET SNAPSHOT & KEY BUYING CRITERIA, 2026–2035
- TABLE 7. GLOBAL VACCINES MARKET, (USD MILLION) (2022-2029)
- TABLE 8. GLOBAL VACCINES MARKET, (USD MILLION) (2030-2035)
- TABLE 9. GLOBAL VACCINES MARKET BY REGION, USD MILLION (2022-2029)
- TABLE 10. GLOBAL VACCINES MARKET SHARE BY REGION, (2022-2029)
- TABLE 11. GLOBAL VACCINES MARKET BY REGION, USD MILLION (2030-2035)
- TABLE 12. GLOBAL VACCINES MARKET SHARE BY REGION, (2030-2035)
- TABLE 13. NORTH AMERICA VACCINES MARKET, (USD MILLION) (2022-2029)
- TABLE 14. NORTH AMERICA VACCINES MARKET, (USD MILLION) (2030-2035)
- TABLE 15. EUROPE VACCINES MARKET, (USD MILLION) (2022-2029)
- TABLE 16. EUROPE VACCINES MARKET, (USD MILLION) (2030-2035)
- TABLE 17. ASIA PACIFIC VACCINES MARKET, (USD MILLION) (2022-2029)
- TABLE 18. ASIA PACIFIC VACCINES MARKET, (USD MILLION) (2030-2035)
- TABLE 19. MIDDLE EAST AND AFRICA VACCINES MARKET, (USD MILLION) (2022-2029)
- TABLE 20. MIDDLE EAST AND AFRICA VACCINES MARKET, (USD MILLION) (2030-2035)
- TABLE 21. LATIN AMERICA VACCINES MARKET, (USD MILLION) (2022-2029)
- TABLE 22. LATIN AMERICA VACCINES MARKET, (USD MILLION) (2030-2035)
- TABLE 23. NORTH AMERICA VACCINES MARKET BY COUNTRY, (2022-2029)
- TABLE 24. NORTH AMERICA VACCINES MARKET SHARE BY COUNTRY, (2022-2029)
- TABLE 25. NORTH AMERICA VACCINES MARKET BY COUNTRY, (2030-2035)
- TABLE 26. NORTH AMERICA VACCINES MARKET SHARE BY COUNTRY, (2030-2035)
- TABLE 27. UNITED STATES VACCINES MARKET, (USD MILLION) (2022-2029)
- TABLE 28. UNITED STATES VACCINES MARKET, (USD MILLION) (2030-2035)
- TABLE 29. CANADA VACCINES MARKET, (USD MILLION) (2022-2029)
- TABLE 30. CANADA VACCINES MARKET, (USD MILLION) (2030-2035)
- TABLE 31. MEXICO VACCINES MARKET, (USD MILLION) (2022-2029)
- TABLE 32. MEXICO VACCINES MARKET, (USD MILLION) (2030-2035)
- TABLE 33. EUROPE VACCINES MARKET BY COUNTRY, (2022-2029)
- TABLE 34. EUROPE VACCINES MARKET SHARE BY COUNTRY, (2022-2029)
- TABLE 35. EUROPE VACCINES MARKET BY COUNTRY, (2030-2035)
- TABLE 36. EUROPE VACCINES MARKET SHARE BY COUNTRY, (2030-2035)
- TABLE 37. UNITED KINGDOM VACCINES MARKET, (USD MILLION) (2022-2029)
- TABLE 38. UNITED KINGDOM VACCINES MARKET, (USD MILLION) (2030-2035)
- TABLE 39. GERMANY VACCINES MARKET, (USD MILLION) (2022-2029)
- TABLE 40. GERMANY VACCINES MARKET, (USD MILLION) (2030-2035)
- TABLE 41. FRANCE VACCINES MARKET, (USD MILLION) (2022-2029)
- TABLE 42. FRANCE VACCINES MARKET, (USD MILLION) (2030-2035)
- TABLE 43. SPAIN VACCINES MARKET, (USD MILLION) (2022-2029)
- TABLE 44. SPAIN VACCINES MARKET, (USD MILLION) (2030-2035)
- TABLE 45. ITALY VACCINES MARKET, (USD MILLION) (2022-2029)
- TABLE 46. ITALY VACCINES MARKET, (USD MILLION) (2030-2035)
- TABLE 47. REST OF EUROPE VACCINES MARKET, (USD MILLION) (2022-2029)
- TABLE 48. REST OF EUROPE VACCINES MARKET, (USD MILLION) (2030-2035)
- TABLE 49. ASIA PACIFIC VACCINES MARKET BY COUNTRY, (2022-2029)
- TABLE 50. ASIA PACIFIC VACCINES MARKET SHARE BY COUNTRY, (2022-2029)
- TABLE 51. ASIA PACIFIC VACCINES MARKET BY COUNTRY, (2030-2035)
- TABLE 52. ASIA PACIFIC VACCINES MARKET SHARE BY COUNTRY, (2030-2035)
- TABLE 53. CHINA VACCINES MARKET, (USD MILLION) (2022-2029)
- TABLE 54. CHINA VACCINES MARKET, (USD MILLION) (2030-2035)
- TABLE 55. INDIA VACCINES MARKET, (USD MILLION) (2022-2029)
- TABLE 56. INDIA VACCINES MARKET, (USD MILLION) (2030-2035)
- TABLE 57. JAPAN VACCINES MARKET, (USD MILLION) (2022-2029)
- TABLE 58. JAPAN VACCINES MARKET, (USD MILLION) (2030-2035)
- TABLE 59. AUSTRALIA VACCINES MARKET, (USD MILLION) (2022-2029)
- TABLE 60. AUSTRALIA VACCINES MARKET, (USD MILLION) (2030-2035)
- TABLE 61. SOUTH KOREA VACCINES MARKET, (USD MILLION) (2022-2029)
- TABLE 62. SOUTH KOREA VACCINES MARKET, (USD MILLION) (2030-2035)
- TABLE 63. REST OF ASIA PACIFIC VACCINES MARKET, (USD MILLION) (2022-2029)
- TABLE 64. REST OF ASIA PACIFIC VACCINES MARKET, (USD MILLION) (2030-2035)
- TABLE 65. MIDDLE EAST AND AFRICA VACCINES MARKET BY COUNTRY, (2022-2029)
- TABLE 66. MIDDLE EAST AND AFRICA VACCINES MARKET SHARE BY COUNTRY, (2022-2029)
- TABLE 67. MIDDLE EAST AND AFRICA VACCINES MARKET BY COUNTRY, (2030-2035)
- TABLE 68. MIDDLE EAST AND AFRICA VACCINES MARKET SHARE BY COUNTRY, (2030-2035)
- TABLE 69. SAUDI ARABIA VACCINES MARKET, (USD MILLION) (2022-2029)
- TABLE 70. SAUDI ARABIA VACCINES MARKET, (USD MILLION) (2030-2035)
- TABLE 71. SOUTH AFRICA VACCINES MARKET, (USD MILLION) (2022-2029)
- TABLE 72. SOUTH AFRICA VACCINES MARKET, (USD MILLION) (2030-2035)
- TABLE 73. REST OF MEA VACCINES MARKET, (USD MILLION) (2022-2029)
- TABLE 74. REST OF MEA VACCINES MARKET, (USD MILLION) (2030-2035)
- TABLE 75. LATIN AMERICA VACCINES MARKET BY COUNTRY, (2022-2029)
- TABLE 76. LATIN AMERICA VACCINES MARKET SHARE BY COUNTRY, (2022-2029)
- TABLE 77. LATIN AMERICA VACCINES MARKET BY COUNTRY, (2030-2035)
- TABLE 78. LATIN AMERICA VACCINES MARKET SHARE BY COUNTRY, (2030-2035)
- TABLE 79. BRAZIL VACCINES MARKET, (USD MILLION) (2022-2029)
- TABLE 80. BRAZIL VACCINES MARKET, (USD MILLION) (2030-2035)
- TABLE 81. ARGENTINA VACCINES MARKET, (USD MILLION) (2022-2029)
- TABLE 82. ARGENTINA VACCINES MARKET, (USD MILLION) (2030-2035)
- TABLE 83. REST OF LATIN AMERICA VACCINES MARKET, (USD MILLION) (2022-2029)
- TABLE 84. REST OF LATIN AMERICA VACCINES MARKET, (USD MILLION) (2030-2035)
- TABLE 85. GLOBAL VACCINES MARKET BY BY TECHNOLOGY, USD MILLION (2022-2029)
- TABLE 86. GLOBAL VACCINES MARKET BY BY TECHNOLOGY, USD MILLION (2030-2035)
- TABLE 87. NORTH AMERICA VACCINES MARKET BY BY TECHNOLOGY, USD MILLION (2022-2029)
- TABLE 88. NORTH AMERICA VACCINES MARKET BY BY TECHNOLOGY, USD MILLION (2030-2035)
- TABLE 89. EUROPE VACCINES MARKET BY BY TECHNOLOGY, USD MILLION (2022-2029)
- TABLE 90. EUROPE VACCINES MARKET BY BY TECHNOLOGY, USD MILLION (2030-2035)
- TABLE 91. ASIA PACIFIC VACCINES MARKET BY BY TECHNOLOGY, USD MILLION (2022-2029)
- TABLE 92. ASIA PACIFIC VACCINES MARKET BY BY TECHNOLOGY, USD MILLION (2030-2035)
- TABLE 93. MIDDLE EAST & AFRICA VACCINES MARKET BY BY TECHNOLOGY, USD MILLION (2022-2029)
- TABLE 94. MIDDLE EAST & AFRICA VACCINES MARKET BY BY TECHNOLOGY, USD MILLION (2030-2035)
- TABLE 95. SOUTH AMERICA VACCINES MARKET BY BY TECHNOLOGY, USD MILLION (2022-2029)
- TABLE 96. SOUTH AMERICA VACCINES MARKET BY BY TECHNOLOGY, USD MILLION (2030-2035)
- TABLE 97. GLOBAL VACCINES MARKET BY BY INDICATION, USD MILLION (2022-2029)
- TABLE 98. GLOBAL VACCINES MARKET BY BY INDICATION, USD MILLION (2030-2035)
- TABLE 99. NORTH AMERICA VACCINES MARKET BY BY INDICATION, USD MILLION (2022-2029)
- TABLE 100. NORTH AMERICA VACCINES MARKET BY BY INDICATION, USD MILLION (2030-2035)
- TABLE 101. EUROPE VACCINES MARKET BY BY INDICATION, USD MILLION (2022-2029)
- TABLE 102. EUROPE VACCINES MARKET BY BY INDICATION, USD MILLION (2030-2035)
- TABLE 103. ASIA PACIFIC VACCINES MARKET BY BY INDICATION, USD MILLION (2022-2029)
- TABLE 104. ASIA PACIFIC VACCINES MARKET BY BY INDICATION, USD MILLION (2030-2035)
- TABLE 105. MIDDLE EAST & AFRICA VACCINES MARKET BY BY INDICATION, USD MILLION (2022-2029)
- TABLE 106. MIDDLE EAST & AFRICA VACCINES MARKET BY BY INDICATION, USD MILLION (2030-2035)
- TABLE 107. SOUTH AMERICA VACCINES MARKET BY BY INDICATION, USD MILLION (2022-2029)
- TABLE 108. SOUTH AMERICA VACCINES MARKET BY BY INDICATION, USD MILLION (2030-2035)
- TABLE 109. GLOBAL VACCINES MARKET BY BY ROUTE OF ADMINISTRATION, USD MILLION (2022-2029)
- TABLE 110. GLOBAL VACCINES MARKET BY BY ROUTE OF ADMINISTRATION, USD MILLION (2030-2035)
- TABLE 111. NORTH AMERICA VACCINES MARKET BY BY ROUTE OF ADMINISTRATION, USD MILLION (2022-2029)
- TABLE 112. NORTH AMERICA VACCINES MARKET BY BY ROUTE OF ADMINISTRATION, USD MILLION (2030-2035)
- TABLE 113. EUROPE VACCINES MARKET BY BY ROUTE OF ADMINISTRATION, USD MILLION (2022-2029)
- TABLE 114. EUROPE VACCINES MARKET BY BY ROUTE OF ADMINISTRATION, USD MILLION (2030-2035)
- TABLE 115. ASIA PACIFIC VACCINES MARKET BY BY ROUTE OF ADMINISTRATION, USD MILLION (2022-2029)
- TABLE 116. ASIA PACIFIC VACCINES MARKET BY BY ROUTE OF ADMINISTRATION, USD MILLION (2030-2035)
- TABLE 117. MIDDLE EAST & AFRICA VACCINES MARKET BY BY ROUTE OF ADMINISTRATION, USD MILLION (2022-2029)
- TABLE 118. MIDDLE EAST & AFRICA VACCINES MARKET BY BY ROUTE OF ADMINISTRATION, USD MILLION (2030-2035)
- TABLE 119. SOUTH AMERICA VACCINES MARKET BY BY ROUTE OF ADMINISTRATION, USD MILLION (2022-2029)
- TABLE 120. SOUTH AMERICA VACCINES MARKET BY BY ROUTE OF ADMINISTRATION, USD MILLION (2030-2035)
LIST OF FIGURES
- FIGURE 1. MARKET OVERVIEW
- FIGURE 2. REGIONAL SHARE
- FIGURE 3. MARKET REVENUE (USD MILLION)
- FIGURE 4. DROC OF VACCINES MARKET ANALYSIS
- FIGURE 5. SWOT ANALYSIS
- FIGURE 6. PESTEL ANALYSIS
- FIGURE 7. PORTER'S FIVE FORCES ANALYSIS
- FIGURE 8. COVID V, U, W AND L ANALYSIS
- FIGURE 9. LEADING COMPANIES
- FIGURE 10. REGIONAL ANALYSIS
- FIGURE 11. COUNTRY ANALYSIS
- FIGURE 12. GLOBAL VACCINES MARKET, (2022-2029), (USD MILLION)
- FIGURE 13. GLOBAL VACCINES MARKET, (2030-2035), (USD MILLION)
- FIGURE 14. GLOBAL VACCINES MARKET, (2022-2029), (USD MILLION), BY REGION
- FIGURE 15. GLOBAL VACCINES MARKET SHARE, (2026), BY REGION
- FIGURE 16. GLOBAL VACCINES MARKET, (2030-2035), (USD MILLION), BY REGION
- FIGURE 17. GLOBAL VACCINES MARKET SHARE, (2035), BY REGION
- FIGURE 18. NORTH AMERICA VACCINES MARKET, (2022-2029), (USD MILLION)
- FIGURE 19. NORTH AMERICA VACCINES MARKET, (2030-2035), (USD MILLION)
- FIGURE 20. EUROPE VACCINES MARKET, (2022-2029), (USD MILLION)
- FIGURE 21. EUROPE VACCINES MARKET, (2030-2035), (USD MILLION)
- FIGURE 22. ASIA PACIFIC VACCINES MARKET, (2022-2029), (USD MILLION)
- FIGURE 23. ASIA PACIFIC VACCINES MARKET, (2030-2035), (USD MILLION)
- FIGURE 24. MIDDLE EAST AND AFRICA VACCINES MARKET, (2022-2029), (USD MILLION)
- FIGURE 25. MIDDLE EAST AND AFRICA VACCINES MARKET, (2030-2035), (USD MILLION)
- FIGURE 26. LATIN AMERICA VACCINES MARKET, (2022-2029), (USD MILLION)
- FIGURE 27. LATIN AMERICA VACCINES MARKET, (2030-2035), (USD MILLION)
- FIGURE 28. NORTH AMERICA VACCINES MARKET, (2022-2029), (USD MILLION), BY COUNTRY
- FIGURE 29. NORTH AMERICA VACCINES MARKET SHARE, (2026), BY COUNTRY
- FIGURE 30. NORTH AMERICA VACCINES MARKET, (2030-2035), (USD MILLION), BY COUNTRY
- FIGURE 31. NORTH AMERICA VACCINES MARKET SHARE, (2035), BY COUNTRY
- FIGURE 32. UNITED STATES VACCINES MARKET, (2022-2029), (USD MILLION)
- FIGURE 33. UNITED STATES VACCINES MARKET, (2030-2035), (USD MILLION)
- FIGURE 34. CANADA VACCINES MARKET, (2022-2029), (USD MILLION)
- FIGURE 35. CANADA VACCINES MARKET, (2030-2035), (USD MILLION)
- FIGURE 36. MEXICO VACCINES MARKET, (2022-2029), (USD MILLION)
- FIGURE 37. MEXICO VACCINES MARKET, (2030-2035), (USD MILLION)
- FIGURE 38. EUROPE VACCINES MARKET, (2022-2029), (USD MILLION), BY COUNTRY
- FIGURE 39. EUROPE VACCINES MARKET SHARE, (2026), BY COUNTRY
- FIGURE 40. EUROPE VACCINES MARKET, (2030-2035), (USD MILLION), BY COUNTRY
- FIGURE 41. EUROPE VACCINES MARKET SHARE, (2035), BY COUNTRY
- FIGURE 42. UNITED KINGDOM VACCINES MARKET, (2022-2029), (USD MILLION)
- FIGURE 43. UNITED KINGDOM VACCINES MARKET, (2030-2035), (USD MILLION)
- FIGURE 44. GERMANY VACCINES MARKET, (2022-2029), (USD MILLION)
- FIGURE 45. GERMANY VACCINES MARKET, (2030-2035), (USD MILLION)
- FIGURE 46. FRANCE VACCINES MARKET, (2022-2029), (USD MILLION)
- FIGURE 47. FRANCE VACCINES MARKET, (2030-2035), (USD MILLION)
- FIGURE 48. SPAIN VACCINES MARKET, (2022-2029), (USD MILLION)
- FIGURE 49. SPAIN VACCINES MARKET, (2030-2035), (USD MILLION)
- FIGURE 50. ITALY VACCINES MARKET, (2022-2029), (USD MILLION)
- FIGURE 51. ITALY VACCINES MARKET, (2030-2035), (USD MILLION)
- FIGURE 52. REST OF EUROPE VACCINES MARKET, (2022-2029), (USD MILLION)
- FIGURE 53. REST OF EUROPE VACCINES MARKET, (2030-2035), (USD MILLION)
- FIGURE 54. ASIA PACIFIC VACCINES MARKET, (2022-2029), (USD MILLION), BY COUNTRY
- FIGURE 55. ASIA PACIFIC VACCINES MARKET SHARE, (2026), BY COUNTRY
- FIGURE 56. ASIA PACIFIC VACCINES MARKET, (2030-2035), (USD MILLION), BY COUNTRY
- FIGURE 57. ASIA PACIFIC VACCINES MARKET SHARE, (2035), BY COUNTRY
- FIGURE 58. CHINA VACCINES MARKET, (2022-2029), (USD MILLION)
- FIGURE 59. CHINA VACCINES MARKET, (2030-2035), (USD MILLION)
- FIGURE 60. INDIA VACCINES MARKET, (2022-2029), (USD MILLION)
- FIGURE 61. INDIA VACCINES MARKET, (2030-2035), (USD MILLION)
- FIGURE 62. JAPAN VACCINES MARKET, (2022-2029), (USD MILLION)
- FIGURE 63. JAPAN VACCINES MARKET, (2030-2035), (USD MILLION)
- FIGURE 64. AUSTRALIA VACCINES MARKET, (2022-2029), (USD MILLION)
- FIGURE 65. AUSTRALIA VACCINES MARKET, (2030-2035), (USD MILLION)
- FIGURE 66. SOUTH KOREA VACCINES MARKET, (2022-2029), (USD MILLION)
- FIGURE 67. SOUTH KOREA VACCINES MARKET, (2030-2035), (USD MILLION)
- FIGURE 68. REST OF ASIA PACIFIC VACCINES MARKET, (2022-2029), (USD MILLION)
- FIGURE 69. REST OF ASIA PACIFIC VACCINES MARKET, (2030-2035), (USD MILLION)
- FIGURE 70. MIDDLE EAST AND AFRICA VACCINES MARKET, (2022-2029), (USD MILLION), BY COUNTRY
- FIGURE 71. MIDDLE EAST AND AFRICA VACCINES MARKET SHARE, (2026), BY COUNTRY
- FIGURE 72. MIDDLE EAST AND AFRICA VACCINES MARKET, (2030-2035), (USD MILLION), BY COUNTRY
- FIGURE 73. MIDDLE EAST AND AFRICA VACCINES MARKET SHARE, (2035), BY COUNTRY
- FIGURE 74. SAUDI ARABIA VACCINES MARKET, (2022-2029), (USD MILLION)
- FIGURE 75. SAUDI ARABIA VACCINES MARKET, (2030-2035), (USD MILLION)
- FIGURE 76. SOUTH AFRICA VACCINES MARKET, (2022-2029), (USD MILLION)
- FIGURE 77. SOUTH AFRICA VACCINES MARKET, (2030-2035), (USD MILLION)
- FIGURE 78. REST OF MEA VACCINES MARKET, (2022-2029), (USD MILLION)
- FIGURE 79. REST OF MEA VACCINES MARKET, (2030-2035), (USD MILLION)
- FIGURE 80. LATIN AMERICA VACCINES MARKET, (2022-2029), (USD MILLION), BY COUNTRY
- FIGURE 81. LATIN AMERICA VACCINES MARKET SHARE, (2026), BY COUNTRY
- FIGURE 82. LATIN AMERICA VACCINES MARKET, (2030-2035), (USD MILLION), BY COUNTRY
- FIGURE 83. LATIN AMERICA VACCINES MARKET SHARE, (2035), BY COUNTRY
- FIGURE 84. BRAZIL VACCINES MARKET, (2022-2029), (USD MILLION)
- FIGURE 85. BRAZIL VACCINES MARKET, (2030-2035), (USD MILLION)
- FIGURE 86. ARGENTINA VACCINES MARKET, (2022-2029), (USD MILLION)
- FIGURE 87. ARGENTINA VACCINES MARKET, (2030-2035), (USD MILLION)
- FIGURE 88. REST OF LATIN AMERICA VACCINES MARKET, (2022-2029), (USD MILLION)
- FIGURE 89. REST OF LATIN AMERICA VACCINES MARKET, (2030-2035), (USD MILLION)
Research Methodology
Our research methodology is carefully designed to deliver the clients with the most accurate, relevant, and actionable market insights to enable clear decision-making and leveraging of opportunities in the markets. We believe consistency, depth in analysis, and a tailored approach in each report are what help set us apart in the industry. The research methodology is based on an integrating research process consisting of in-depth data collection, a complex analysis, and a stringent validation system.
Data Collection
Data collection forms the basis of our study and gathers diverse authentic data to build the basis for deeper study in terms of market trends, competitive landscape, and growth prospects. Data collection takes place through two channels of main activities as follows:
Primary Data Collection
Primary data collection allows collecting real-time and firsthand information from market participants. This is an engagement process conducted by our team with other industry stakeholders, where a much deeper insight than any published data is pursued. This process includes:
- Direct Interviews – We interview the key decision-makers such as CEOs, product managers, innovation heads, and marketing directors to gather both qualitative and quantitative information. The questionnaire covers emerging trends, customer preferences, regulatory impact, and competitors’ strategies.
- Demand and Supply-Side Inputs – Interviews and surveys with supply and demand-side stakeholders provide a balanced view of prevailing market conditions, including feedback from manufacturers, distributors, suppliers, and end-users.
- Expert Opinions – Consultations with industry experts and domain specialists provide insights into future market direction, risks, and opportunities.
- Focus Groups and Online Surveys – Focus groups and surveys are used to understand consumer preferences and adoption probability of new products or services.
Primary research forms the core of our data validation process by offering direct insights into the market, addressing limitations in secondary data, and allowing for an adaptable research process.
Secondary Data Collection
Secondary research serves as a robust foundation for understanding market context, historical data, and larger trends. It involves systematic gathering of existing information from verified sources.
- Industry Reports and Publications – Market reports, white papers, and case studies from credible sources provide a broad view of the market landscape and key players.
- Government and Public Records – Data from government agencies and regulatory bodies helps analyze economic factors and policy impacts.
- News and Media Outlets – Monitoring news articles, press releases, and media reports keeps us updated on market developments and M&A activity.
- Proprietary and Paid Databases – Databases such as Bloomberg, Factiva, D&B Hoovers, and Thomson Reuters provide validated and cross-referenced data.
- Financial Reports and SEC Filings – Financial statements, annual reports, and investor presentations provide insights into revenue structures and profitability.
This combination of primary and secondary data sources enables us to provide a comprehensive view of the market, supported by authenticated information across multiple sources.
Data Analysis Techniques
With the data collected, we initiate a rigorous analysis phase. We analyze market dynamics, growth patterns, and future performance using analytical models and statistical tools.
Top-Down and Bottom-Up Market Sizing Approaches
- Top-Down Approach – Starts with global market size and distributes it across segments using macro-level trends and established proportions.
- Bottom-Up Approach – Aggregates company-level and country-level revenue data to build regional and global market estimates.
These two approaches are cross-validated to remove inconsistencies and ensure accurate market estimation.
Forecasting Models and Market Dynamics Analysis
- Time-Series Analysis – Models historical trends, seasonality, and demand cycles.
- Econometric and Judgmental Forecasting – Combines economic models with expert-driven adjustments.
- Delphi Method – Uses iterative expert input to generate balanced market forecasts.
Data Triangulation and Validation
- Multi-source cross-verification of all data points
- Use of quantitative and qualitative validation techniques
- Sample validation through expert and stakeholder feedback
Market Analysis and Sizing Estimation
- Detailed segmentation analysis
- Competitive landscape evaluation
- Revenue modeling using TAM, SAM, and SOM frameworks
Quality Assurance and Final Review
- Data accuracy and consistency checks
- Content, language, and structure review
- Client-specific customization and refinement
Continuous Improvement in Methodology
We continuously refine our research methodologies based on evolving market conditions, client feedback, and technological advancements. This ensures our research remains accurate, relevant, and aligned with industry standards.
Vaccines Market Report Scope & Segmentation
| Attributes | Details |
|---|---|
| Market Size (Current)Current market valuation | US$ 88.4 Billion in 2026 |
| Market Size (Forecast)Projected market valuation | US$ 126.26 Billion in 2035 |
| Growth RateCompound Annual Growth Rate | CAGR of 4.04% from 2026 to 2035 |
| Forecast PeriodAnalysis timeline | 2026 – 2035 |
| Base YearReference year for analysis | 2025 |
| Historical Data AvailablePast market data availability | Yes |
| Regional ScopeGeographical coverage | Global |
| Segments CoveredMarket segments analyzed | By Technology
By Indication
By Route of Administration
|
Leading companies covered in this report
- GSK
- Pfizer
- Merck and Co.
- Sanofi
- Moderna
- Johnson and Johnson
- AstraZeneca
- Serum Institute of India
- CSL Limited
Frequently Asked Questions
Common questions about this report
The study period covers historical insights and forecast projections for the period 2026-2035.
The global Vaccines Market market is expected to grow at a CAGR of 4.04% during the forecast period 2026-2035.
The report offers comprehensive market segmentation analysis across key categories and sub-segments relevant to the industry, along with regional and competitive insights.
The market is projected to reach 126.26 Billion by 2035.
Key players in the Vaccines Market include GSK, Pfizer, Merck and Co., Sanofi, Moderna, Johnson and Johnson, AstraZeneca, Serum Institute of India, and CSL Limited.
North America, Europe, and Asia Pacific are key regions covered in the report, including regional trends, market share, and growth opportunities.
Growing demand, technological advancements, changing consumer preferences, and increasing investments are some of the major factors supporting the growth of the Vaccines Market market.
Yes, the report includes company profiling, competitive landscape analysis, strategic developments, mergers & acquisitions, product launches, and market positioning of leading industry participants.
The report is prepared using a combination of primary research, secondary research, expert interviews, industry databases, company annual reports, and proprietary market analysis models.
Yes, report customization options are available based on specific business objectives, geographic focus, competitive benchmarking requirements, and additional market segmentation needs.
Yes, the report is available in both PDF and Excel formats. The Excel file includes all market data tables, forecasts, and segment-wise data for easy analysis.
Yes, you can request a free sample report which includes an overview, table of contents, and sample data pages to help you evaluate the report before making a purchase decision.
About the Author
Market research expert with years of industry experience

Dipali Bhingare serves as the Market Research Director at Econ Market Research. With a focus on translating complex global economic shifts into actionable business intelligence, she oversees the strategic direction of comprehensive market studies. Her work empowers organizations to navigate volatile industries through data-driven forecasting and deep-dive competitive analysis.










